These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504 [TBL] [Abstract][Full Text] [Related]
4. [Combination therapy of vincristine and diltiazem in children with acute lymphocytic leukemia resistant to vincristine during bone marrow relapse]. Yaoi K; Yamamoto S; Tatsumi K; Inoue A; Wakamiya E; Konishi K; Mino M Rinsho Ketsueki; 1984 Oct; 25(10):1574-80. PubMed ID: 6596445 [No Abstract] [Full Text] [Related]
6. [Recent therapy for refractory myeloma]. Togawa A Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332 [TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Kim SJ; Kim J; Cho Y; Seo BK; Kim BS Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191 [TBL] [Abstract][Full Text] [Related]
8. [Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma]. Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV Vopr Onkol; 2004; 50(6):726-8. PubMed ID: 15755073 [TBL] [Abstract][Full Text] [Related]
11. [Granulocyte-colony stimulating factor-producing myeloma with clinical manifestations mimicking chronic neutrophilic leukemia]. Kusaba N; Yoshida H; Ohkubo F; Mishima K; Shimamastu K; Okamura T; Sata M Rinsho Ketsueki; 2004 Mar; 45(3):228-32. PubMed ID: 15103937 [TBL] [Abstract][Full Text] [Related]
12. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies. Vey N; De Prijck B; Faucher C; Stoppa AM; Sainty D; Lafage M; Bouabdallah R; Chabannon C; Camerlo J; Gastaut JA; Maraninchi D; Blaise D Bone Marrow Transplant; 1996 Sep; 18(3):495-9. PubMed ID: 8879608 [TBL] [Abstract][Full Text] [Related]
13. Adenosine deaminase activity in chronic lymphocytic leukemia: evaluation of lymphocytic ADA during and after treatment. Liso V; Specchia G; Pavone V; Garribba P; Riezzo A; Ferrannini A Haematologica; 1983; 68(4):487-94. PubMed ID: 6414899 [No Abstract] [Full Text] [Related]
14. [Allogeneic bone marrow transplantation for the treatment of acute lymphoblastic leukemia. A comparison of bone marrow transplantation with conventional chemotherapy]. Yoshida T; Harada M; Funada H; Matue G; Shiobara S; Ishino C; Ohtake S; Odaka K; Teshima H; Kondo K Rinsho Ketsueki; 1984 Mar; 25(3):337-45. PubMed ID: 6381788 [No Abstract] [Full Text] [Related]
15. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361 [TBL] [Abstract][Full Text] [Related]
16. [Myeloma with extramedullary extension coinciding with the normalization of serum paraproteins after treatment]. Bernat S; Gozalbo T; García-Boyero R; Guinot M Sangre (Barc); 1998 Feb; 43(1):96-7. PubMed ID: 9577192 [No Abstract] [Full Text] [Related]
17. Refractory multiple myeloma treated with homoharringtonine: report of two cases. Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891 [No Abstract] [Full Text] [Related]